.png)
April 26, 2022 – The first paper on the Benzodiazepine Survey of 2018-2019 was just published on April 25, 2022, titled: “Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey.” Our team has been working on this research for three years now, and finally, we have the first paper published in the journal “Therapeutic Advances in Psychopharmacology.” And this is just the first, many more are slated to follow. I was grateful and humbled to be part of this team and to have the ability to learn so much more about the processes and effects of benzodiazepines from such amazing people. The team behind this paper is some of the same people who are working on the definition and research behind the new term, BIND (Benzodiazepine-Induced Neurological Dysfunction).
Special thanks should go out to the originators of the survey, Christy Huff, M. D. (BIC), and Jane McCoubrie, Ph.D. And equally so, to Bernie Silvernail and the Alliance for Benzodiazepine Best Practices for sponsoring the work and leading the charge to get these papers completed and published.
Alistair J. Reid Finlayson, M.D. and Peter R. Martin, M.D. round out the author team and educate me on the medical side of benzos every week I have the privilege to meet with them. These doctors “get it,” and have seen the harm these drugs have caused first-hand. Thank you.
And last, but by all means, not least, the individuals who took the survey deserve a huge thanks. You all shared your experiences with the survey team and made this survey count. Much like the podcast, you are the heart and soul of this survey. You rock!!!
Talk soon, D 🙂